Enbrel


Also found in: Thesaurus, Medical, Wikipedia.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.Enbrel - a genetically engineered anti-TNF compound (trade name Enbrel) consisting of receptors that bind TNF; it is injected twice a week in the treatment of rheumatoid arthritis
anti-TNF compound - a class of drugs that block the action of tumor necrosis factor (TNF); used in cases of rheumatoid arthritis because TNF instigates inflammation of the joints
brand, brand name, marque, trade name - a name given to a product or service
References in periodicals archive ?
ENBREL data focus on step-down dosing compared with a high-dose regimen and patient-reported outcomes of treatment with ENBREL compared to treatment with ENBREL in combination with topical therapies.
CHMP Recommends Approval of a Continuous Dosing Regimen Option for Enbrel In Plaque Psoriasis, and a New Pre-Filled Pen Delivery Device
said Friday that the company is a step closer to receiving approval in Europe to market Enbrel and Mimpara for the treatment of skin and kidney conditions.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Amgen (NASDAQ:AMGN) today announced the publication of data from the COMET (COmbination of Methotrexate and ETanercept in Active Early Rheumatoid Arthritis) trial demonstrating that half of patients treated with the combination of ENBREL and methotrexate achieved Disease Activity Score (DAS) clinical remission and nearly all had no progression of joint damage.
Moderate to severe rheumatoid arthritis (RA) places a significant burden on patients, and we are pleased that ENBREL remains the number one most prescribed biologic among rheumatologists to help reduce pain and help stop the progression of joint damage in these patients," said Sean E.
New Data Add to the Body of Evidence That Show That Enbrel (Etanercept) Clears Skin and Can Sustain This Efficacy Over Time
THOUSAND OAKS - Patients taking Amgen's rheumatoid arthritis drug Enbrel saw the disease go into clinical remission after two years of therapy, according to a study released Thursday.
Food and Drug Administration's (FDA) Dermatologic and Ophthalmologic Drug Advisory Committee (DODAC) regarding the expanded use of ENBREL in treating pediatric patients with chronic moderate to severe plaque psoriasis.
PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low disease activity (LDA) or clinical remission on combination Enbrel (etanercept) plus methotrexate (MTX) in Period one and were randomized to continue on ENBREL plus MTX or MTX alone in Period two.
Data From Another Study Supported the use of ENBREL for up to Five Years in Ankylosing Spondylitis Patients
The Thousand Oaks biotechnology giant added Enbrel to its portfolio when the company acquired Immunex in 2002.
ENBREL Reviewed As Potential New Treatment Option for Children and Adolescents with Chronic Moderate to Severe Plaque Psoriasis Who Have Tried Another Therapy